Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration

European Journal of Endocrinology

Volumn 159, Issue 3, 2008, Pages 283-291

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   Berti, Piero ^a   Materazzi, Gabriele ^a   Marchetti, Ivo ^b   Ugolini, Clara ^a   Basolo, Fulvio ^a   Miccoli, Paolo ^a   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; B RAF KINASE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; ROSIGLITAZONE; BRAF PROTEIN, HUMAN;

ANAPLASTIC CARCINOMA; ARTICLE; ASPIRATION BIOPSY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INOPERABLE CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; THYROID CANCER; CARCINOMA; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; NEEDLE BIOPSY; PATHOLOGY; THYROID TUMOR;

ANTINEOPLASTIC AGENTS; BIOPSY, FINE-NEEDLE; CARCINOMA; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF; THIAZOLIDINEDIONES; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 53249129499     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0190     Document Type: Article

References (49)

1. Haigh PI, Ituarte PH, Wu HS, Trescler PA, Posner MD, Quivey JM, Duh QY & Clark OH. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001 91 2335-2342.
2. Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F & Monden M. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head and Neck 1996 18 36-41.
3. Junor El, Paul J & Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. European Journal of Surgical Oncology 1992 18 83-88.
4. Giuffrida D & Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Annals of Oncology 2000 11 1083-1089.
5. Busnardo B, Daniele O, Pelizzo MR, Mazzarotto R, Nacamulli D, Devido D, Mian C & Girelli ME. A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. Journal of Endocrinological Investigation 2000 23 755-761.
6. Haddad R, Mahadevan A, Posner MR & Sullivan C. Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. American Journal of Clinical Oncology 2005 28 104.
7. Newell DR. Flasks, fibres and flanks - pre-clinical tumour models for predicting clinical antitumour activity. British Journal of Cancer 2001 84 1289-1290.
8. Dollner R, Granzow C, Werner JA & Dietz A. Is there a role for chemosensitivity tests in head and neck cancer? Onkologie 2004 27 310-315.
9. Schroyens W, Tueni E, Dodion P, Bodecker R, Stoessel F & Klastersky J. Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer. European Journal of Cancer 1990 26 834-838.
10. Voigt W, Bulankin A, Muller T, Schoeber C, Grothey A, HoangVu C & Schmoll HJ. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clinical Cancer Research 2000 6 2087-2093.
11. Ain KB, Egorin MJ & DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000 10 587-594.
12. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA, Williams SF, Haugen BR, Klopper JP & Smallridge RC. Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAFI/C1F1. Oncogene 2006 25 2304-2317.
13. Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G & Berti P. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbeek's Archives of Surgery 2007 392 397-404.
14. Grommes C, Landreth GE & Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncology 2004 5 419-429.
15. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Scrio M & Ferrannini E. Interferon-gammainducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated. receptor-gamma agonists. Journal of Clinical Endocrinology and Metabolism 2006 91 614-620.
16. Ohta K, Endo T, Haraguchi K, Hershman JM & Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. Journal of Clinical Endocrinology and Metabolism 2001 86 2170-2177.
17. Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM & Hangen BR. Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Molecular Cancer Therapeutics 2004 3 1011-1020.
18. Philips JC, Petite C, Willi JP, Buchegger F & Meier CA. Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nuclear Medicine Communications 2004 25 1183-1186.
19. Park JW, Zarnegar R, Kanauchi H, Wong MG, Hyun WC, Ginzinger DG, Lobo M, Cotter P, Duh QY & Clark OH. Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005 15 222-231.
20. Frohlich E, Machicao F & Wahl R. Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocrine-Related Cancer 2005 12 291-303.
21. Hayashi N, Nakamori S, Hiraoka N, Tsujie M, Xundi X, Takano T, Amino N, Sakon M & Monden M. Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. International Journal of Oncology 2004 24 89-95.
22. Sherman SI. Thyroid carcinoma. Lancet 2003 361 501-511.
23. Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, Berti P, Materazzi G, Miccoli P, Santoro M & Basolo F. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 3511-3516.
24. Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YF, Troncone G, Palombini L, Basolo F & Santoro M. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2004 89 5175-5180.
25. Basolo F, Fiore L, Calvo S, Falcone V, Conaldi PG, Fontanini G, Caligo AM, Merlo G, Gluzman Y & Toniolo A. Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. British Journal of Cancer 1996 73 1356-1361.
26. Berridge MV, Herst PM & Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnology Annual Review 2005 11 127-152.
27. Gutiérrez-Cañas I, Rodríguez-Henche N, Bolaños O, Carmena MJ, Prieto JC & Juarranz MG. VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal. British Journal of Pharmacology 2003 139 1050-1058.
28. Kamikubo Y, Takaori-Kondo A, Uchiyama T & Hori T. Inhibition of cell growth by conditional expression of kpm, a human homologue of Drosophila warts/lats tumor suppressor. Journal of Biological Chemistry 2003 278 17609-17614.
29. Gillman G. The Pharmacological Basis of Therapeutics New York: McGraw-Hill, 2005.
30. Li W, Lam MS, Birkeland A, Riffel A, Montana L, Sullivan ME & Post JM. Cell-based assays for profiling activity and safety properties of cancer drugs. Journal of Pharmacological and Toxicological Methods 2006 54 313-319.
31. Fridborg H, Nygren P & Larsson R. Relationship between pharmacokinctic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anticancer Drugs 1995 6 64-69.
32. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W Raber MN et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. Journal of Clinical Oncology 1991 9 491-498.
33. Millward MJ, Newell DR, Mummaneni V, Igwemezie LN, Balmanno K, Charlton CJ, Gumbrell L, Lind MJ, Chapman F Proctor M et al. Phase I and pharmacokinetic study of a watersoluble etoposide prodrug, etoposide phosphate (BMY-40481). European Journal of Cancer 1995 31A 2409-2411.
34. Force TCT. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocrine Practice 2001 7 202-220.
35. Bravo SB, García-Rendueles ME, Seoane R, Dosil V, Cameselle-Teijeiro J, López-Lázaro L, Zalvide J, Barreiro F, Pombo CM & Alvarez CV. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma. Clinical Cancer Research 2005 11 7664-7673.
36. Karwowski JK, Nowels KW, McDougall IR & Weigel RJ. Needle track seeding of papillary thyroid carcinoma from fine needle aspiration biopsy. A case report. Acta Cytologica 2002 46 591-595.
37. Uchida N, Suda T, Inoue T, Fujiwara Y & Ishiguro K. Needle track dissemination of follicular thyroid carcinoma following fine-needle aspiration biopsy: report of a case. Surgery Today 2007 37 34-37.
38. Wu M, Zhang Z & Che W. Suppression of a DNA base excision repair gene, hOGG1, increases bleomycin sensitivity of human lung cancer cell line. Toxicology and Applied Pharmacology 2008 228 395-402.
39. Pani E, Stojic L, El-Shemerly M, Jiricny J & Ferrari S. Mismatch repair status and the response of human cells to cisplatin. Cell Cycle 2007 6 1796-1802.
40. Voigt W, Bulankin A, Müller T, Schoeber C, Grothey A, Hoang-Vu C & Schmoll HJ. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clinical Cancer Research 2000 6 2087-2093.
41. Kotchetkov R, Gröschel B, Gmeiner WH, Krivtchik AA, Trump E, Bitoova M, Cinatl J, Kornhuber B & Cinatl J. Antineoplastic activity of a novel multimeric gemcitabine-monophosphate prodrug against thyroid cancer cells in vitro. Anticancer Research 2000 20 2915-2922.
42. Lomonaco SL, Kahana S, Blass M, Brody Y, Okhrimenko H, Xiang C, Finniss S, Blumberg PM, Lee HK & Brodie C. Phosphorylation of PKCdelta on distinct tyrosine residues induces sustained activation of Erk 1/2 via downregulation of MKP-1: role in the apoptotic effect of etoposide. Journal of Biological Chemistry 2008 283 17731-17739.
43. Martelli ML, Iuliano R, Le Pera I, Sama i, Monaco C, Cammarota S, Kroll T, Chiariotti L, Santoro M & Fusco A. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism 2002 87 4728-4735.
44. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R & Belfiore A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 2006 147 4463-4475.
45. Otto C, Lehrke M & Goke B. Novel insulin sensitizers: pharmacogenomic aspects. Pharmacogenomics 2002 3 99-116.
46. Huang JW, Shiau CW, Yang YT, Kulp SK, Chen KF, Brueggemeier RW, Shapiro CL & Chen CS. Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Molecular Pharmacology 2005 67 1342-1348.
47. Davies GF, Roesler WJ, Juurlink BH & Harkness TA. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leukemia and Lymphoma 2005 46 1199-1206.
48. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM & Santoro M. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clinical Cancer Research 2006 12 1623-1629.
49. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D & Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology 2004 17 1359-1363.